The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Improving outcomes for patients with R/R myeloma
In this video, Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the challenges associated with treating patients with relapsed/refractory (R/R) myeloma. Dr Ramasamy first discusses the psychological burden of relapsed disease, and then mentions the promise of novel combination therapies in improving treatment options for these patients. Following this, Dr Ramasamy explains the need to improve access to BCMA-targeted therapies and the excitement surrounding the future use of chimeric antigen receptor T-cell (CAR-T) therapy in patients who are triple-class refractory. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
